drugset / Trial / NCT02128724

Palliative Thoracic Radiotherapy Plus BKM120

NCT02128724

NaSingle-groupOpen-labelTreatment

Summary

This study will test whether a drug called BKM120/buparlisib is a safe and effective treatment when given to lung cancer patients having radiotherapy treatment. The trial will identify which of three possible doses of buparlisib is best to give with lung radiotherapy.

Timeline

Start
2013-04
Primary completion
2017-10-17
Completion
2017-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Buparlisib Small molecule 50 mg Oral
Subject Buparlisib Small molecule 80 mg Oral
Subject Buparlisib Small molecule 100 mg Oral